Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.

Details

Ressource 1Download: BIB_46FD8A8E7D97.P001.pdf (421.69 [Ko])
State: Serval
Version: author
Serval ID
serval:BIB_46FD8A8E7D97
Type
Article: article from journal or magazin.
Collection
Publications
Title
Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.
Journal
Molecular Cancer
Author(s)
Loisel S., André P.A., Golay J., Buchegger F., Kadouche J., Cérutti M., Bologna L., Kosinski M., Viertl D., Delaloye A.B., Berthou C., Mach J.P., Boumsell L.
ISSN
1476-4598 (Electronic)
ISSN-L
1476-4598
Publication state
Published
Issued date
2011
Volume
10
Pages
42
Language
english
Abstract
Background: The increasing availability of different monoclonal antibodies (mAbs) opens the way to more specific biologic therapy of cancer patients. However, despite the significant success of therapy in breast and ovarian carcinomas with anti-HER2 mAbs as well as in non-Hodkin B cell lymphomas with anti-CD20 mAbs, certain B cell malignancies such as B chronic lymphocytic leukaemia (B-CLL) respond poorly to anti-CD20 mAb, due to the low surface expression of this molecule. Thus, new mAbs adapted to each types of tumour will help to develop personalised mAb treatment. To this aim, we analyse the biological and therapeutic properties of three mAbs directed against the CD5, CD71 or HLA-DR molecules highly expressed on B-CLL cells.
Results: The three mAbs, after purification and radiolabelling demonstrated high and specific binding capacity to various human leukaemia target cells. Further in vitro analysis showed that mAb anti-CD5 induced neither growth inhibition nor apoptosis, mAb anti-CD71 induced proliferation inhibition with no early sign of cell death and mAb anti-HLA-DR induced specific cell aggregation, but without evidence of apoptosis. All three mAbs induced various degrees of ADCC by NK cells, as well as phagocytosis by macrophages. Only the anti-HLA-DR mAb induced complement mediated lysis. Coincubation of different pairs of mAbs did not significantly modify the in vitro results. In contrast with these discrete and heterogeneous in vitro effects, in vivo the three mAbs demonstrated marked anti-tumour efficacy and prolongation of mice survival in two models of SCID mice, grafted either intraperitoneally or intravenously with the CD5 transfected JOK1-5.3 cells. This cell line was derived from a human hairy cell leukaemia, a type of malignancy known to have very similar biological properties as the B-CLL, whose cells constitutively express CD5. Interestingly, the combined injection of anti-CD5 with anti-HLA-DR or with anti-CD71 led to longer mouse survival, as compared to single mAb injection, up to complete inhibition of tumour growth in 100% mice treated with both anti-HLA-DR and anti-CD5.
Conclusions: Altogether these data suggest that the combined use of two mAbs, such as anti-HLA-DR and anti-CD5, may significantly enhance their therapeutic potential.
Keywords
Animals, Antibodies, Monoclonal/pharmacology, Antibody-Dependent Cell Cytotoxicity/immunology, Antigens, Surface/immunology, Antineoplastic Agents/pharmacology, Cell Line, Tumor, Complement Activation/drug effects, Complement Activation/immunology, Humans, Iodine Radioisotopes, Leukemia, B-Cell/physiopathology, Lymphoma/physiopathology, Macrophages/drug effects, Macrophages/immunology, Mice, Mice, SCID, Phagocytosis/drug effects, Phagocytosis/immunology, Protein Binding, Survival Analysis, Xenograft Model Antitumor Assays
Pubmed
Web of science
Open Access
Yes
Create date
03/09/2011 21:06
Last modification date
08/05/2019 17:59
Usage data